JAN 2.7 2005 Appli

Atty. Docket No.:

8654/2222

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:
Serial No.:

Wilson et al. 10/790 943

10/790,943 March 2, 2004

Entitled:

Anti-Cancer Combinations

Examiner:

DeLacroix, M.C.

Group Art Unit: 1614

Conf. No.:

2176

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Katie Manzione

Name of Person Mailing Paper

Signature of Person Mailing Paper

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§§ 1.56, 1.97 AND 1.98

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Pursuant to CFR § 1.97(c)(2), because this Statement is being submitted after the mailing of the first Office Action on the merits, the Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 8654/2222.

Date:

January 25, 2006

01/30/2006 RMEBRAHT 00000095 160085 10790943

01 FC:1806

180.00 DA

Respectfully submitted,

Name: Matthew Beaudet Registration No.: 50,649

Customer No.: 29933

Edwards Angell Palmer & Dodge LLP

111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100

JAN 2 7 2006 33

USPTO Form 1 Patent and Trad		S. Department of Commerce	THEBMASICE.	Attorney Docket No.		Serial No.			
INFORM	ATION	DISCLOSURE STAT	EMENT	8654/2222 10/790,943					
				Applicant(s):. Wilson et al.					
				Filing Date: March 2, 2004			Group: 1614		
U.S. PAT	ENT DO	OCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)		
•									
•									
•									
FOREIG	N PATEI	NT DOCUMENTS			-				
Examiner		Document No.	Publication	Country	Class	Subclass	Translation		
Initial			Date				YES	NO	
				-					
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)									
	A.	Hill, et al., "Anti-Vascular Approaches to Solid Tumour Therapy: Evaluation of Vinblastine and Flavone Acetic Acid", International Journal of Cancer (1995), V. 63, No. 1, Pages 119-123.							
	B.	Wilson; "Combination of the Antivascular Agent DMXAA with Radiation and Chemotherapy"; 2000; Internation Journal of Radiation Oncology, Biology and Physics; 46(3): 706.							
·				, = 1010 By 1020 1 1 1 1 1 1	<u>==</u> ,(-)			-	
· · · · · · · · · · · · · · · · · · ·									
EXAMINER					DATE CO	DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.									
**Copies of references not provided at the time of this submission.									